DeepMed Research

UNIVERSITY OF ALABAMA AT BIRMINGHAM

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1969-01-01

Employees: 2K

Market Cap: -

Website: http://www.uab.edu

Clinical Trials

Genetic and Environmental Determinants of Triglycerides (GOLDN)

Completed

Conditions: Cardiovascular Diseases
Atherosclerosis
Heart Diseases

First Posted Date: 2004-05-24

Last Posted Date: 2013-11-19

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 1327

Registration Number: NCT00083369

ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: ISIS 2503

First Posted Date: 2004-05-03

Last Posted Date: 2011-01-04

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 4

Registration Number: NCT00005594

Locations: 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Norris Cotton Cancer Center, Lebanon, New Hampshire, United States

Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: clofarabine
Drug: Ara-C

First Posted Date: 2004-04-23

Last Posted Date: 2012-04-20

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 23

Registration Number: NCT00081822

Locations: 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
The University of Nebraska, Omaha, Nebraska, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

CA-125 in Screening Patients at High Risk for Ovarian Cancer

Withdrawn

Conditions: Ovarian Cancer

First Posted Date: 2004-04-08

Last Posted Date: 2013-08-05

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT00080639

Locations: 🇺🇸
Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States

Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer

Phase 1

Withdrawn

Conditions: Breast Cancer
Gastric Cancer
Lung Cancer
Ovarian Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Biological: MVF-HER-2(628-647)-CRL 1005 vaccine

First Posted Date: 2004-01-08

Last Posted Date: 2013-08-05

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT00017537

Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: 90-Y-ibritumomab tiuxetan
Biological: rituximab
Radiation: indium In 111 ibritumomab tiuxetan

First Posted Date: 2003-12-16

Last Posted Date: 2015-10-21

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 23

Registration Number: NCT00005592

Locations: 🇺🇸
Lombardi Cancer Center, Washington, District of Columbia, United States
🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

Exercise Training in Obesity-prone Black and White Women

Not Applicable

Completed

Conditions: Obesity

Interventions: Behavioral: Diet
Behavioral: Resistance exercise
Behavioral: Aerobic exercise

First Posted Date: 2003-09-01

Last Posted Date: 2017-11-20

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 231

Registration Number: NCT00067873

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

BMS-247550 in Treating Patients With Metastatic Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: ixabepilone
Drug: Fluoropyrimidine
Drug: Irinotecan

First Posted Date: 2003-08-06

Last Posted Date: 2013-08-05

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 2

Registration Number: NCT00033306

Locations: 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Georgia Cancer Specialists, Atlanta, Georgia, United States

CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Breast Cancer
Colorectal Cancer
Lung Cancer
Pancreatic Cancer

First Posted Date: 2003-07-08

Last Posted Date: 2013-04-12

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT00033384

Locations: 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

First Posted Date: 2003-06-06

Last Posted Date: 2015-10-08

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT00062270

Locations: 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy